Open-Angle Glaucoma Clinical Trial
To compare the safety and long-term efficacy of argon laser treatment of the trabecular meshwork with standard medical treatment for primary open-angle glaucoma.
During the last decade, argon laser trabeculoplasty (ALT) has often been used instead of
surgery as the treatment of choice in cases of open-angle glaucoma that could not be
controlled by drugs. ALT treatment consists of tiny laser burns evenly spaced around the
trabecular meshwork. It sometimes has been found to be effective in controlling glaucoma,
although many eyes still require some medical treatment.
The Glaucoma Laser Trial (GLT), a randomized, controlled clinical trial, was conducted to
determine whether ALT is effective in patients with newly diagnosed, primary, open-angle
glaucoma. Each of the 271 patients in the trial received argon laser treatment in one eye
and standard topical medication in the other eye. The eye to be started on medicine and the
eye that would get the laser treatment were randomly selected. The Glaucoma Laser Trial
Followup Study was a followup study of 203 of the 271 patients who enrolled in the Glaucoma
Laser Trial. By the close of the Glaucoma Laser Trial Followup Study, median duration of
followup since diagnosis of primary, open-angle glaucoma was 7 years (maximum, 9 years).
The argon laser treatment was done in two sessions 1 month apart, with one-half of the
trabecular meshwork treated with 45 to 55 laser burns in each session. Patients were seen
for a followup visit 3 months after the first laser treatment and every 3 months thereafter
for a period of at least 2 years. At each visit, examination of the eyes included a check of
intraocular pressure and visual acuity. Visual field examinations were performed 3, 6, and
12 months after randomization and annually thereafter. Disc stereo photographs were taken 6
and 12 months after randomization and annually thereafter.
The results of these examinations determined whether treatment should be changed. If the
pressure in either eye had not been reduced to the desired level, the physician changed the
medication in the eye treated with drops or started the use of drops in the laser-treated
eye according to a standardized procedure being used in the trial. If intraocular pressure
was still not successfully reduced, surgery or further laser treatment may have been
required.
;
Allocation: Randomized, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01157364 -
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
|
Phase 1/Phase 2 | |
| Completed |
NCT02558374 -
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Completed |
NCT01415401 -
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
|
Phase 4 | |
| Completed |
NCT01444040 -
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost
|
Phase 4 | |
| Completed |
NCT01443988 -
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost
|
Phase 4 | |
| Completed |
NCT01455467 -
Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery
|
N/A | |
| Completed |
NCT01487655 -
Waveform Analysis of the Doppler Curve of Ophthalmic Arteries in Glaucoma Patients
|
N/A | |
| Completed |
NCT01340014 -
Patient Preference Comparison of AZARGA Versus COSOPT
|
Phase 4 | |
| Completed |
NCT01426867 -
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
|
Phase 2 | |
| Completed |
NCT01456390 -
Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents
|
N/A | |
| Completed |
NCT01444105 -
Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty
|
N/A | |
| Completed |
NCT00759239 -
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
|
Phase 4 | |
| Completed |
NCT00397241 -
24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
|
Phase 4 | |
| Completed |
NCT00918346 -
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
|
Phase 3 | |
| Completed |
NCT00273481 -
Cosopt Versus Xalacom
|
Phase 4 | |
| Completed |
NCT00716742 -
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
|
N/A | |
| Completed |
NCT02558400 -
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Withdrawn |
NCT03648229 -
African Glaucoma Laser Trial
|
Phase 4 | |
| Completed |
NCT01978600 -
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
|
Phase 4 | |
| Completed |
NCT01699464 -
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
|
Phase 2 |